Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Current Topics in Medicinal Chemistry
Title:Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Volume: 13 Issue: 14
Author(s): Matilde Yanez and Dolores Vina
Affiliation:
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Export Options
About this article
Cite this article as:
Yanez Matilde and Vina Dolores, Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease, Current Topics in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/15680266113139990120
DOI https://dx.doi.org/10.2174/15680266113139990120 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Dihydroartemisinin Ameliorates Decreased Neuroplasticity-Associated Proteins and Excessive Neuronal Apoptosis in APP/PS1 Mice
Current Alzheimer Research Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Arjunolic Acid: A Promising Antioxidant Moiety with Diverse Biological Applications
Current Organic Chemistry Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Glycobiology of Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Common Variants in Toll-Like Receptor 4 Confer Susceptibility to Alzheimer’s Disease in a Han Chinese Population
Current Alzheimer Research Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs
Combinatorial Chemistry & High Throughput Screening Emerging Potential of Naturally Occurring Autophagy Modulators Against Neurodegeneration
Current Pharmaceutical Design Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Current Genomics